AGP Executive Report
Last update: 10 hours agoHepatitis B Trial: Danish researchers are defending a controversial proposed study in Guinea-Bissau that would delay the hepatitis B birth-dose vaccine for half of 14,000 newborns until six weeks of age. The revised protocol has reportedly received ethics approvals, but Health Minister Quinhin Nantote says the government has not authorized the trial. The vaccine has been used safely for decades, and WHO recommends giving it within 24 hours of birth; the study’s disputed status has renewed concerns about infant protection and research oversight.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.